Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muharrem Muftuoglu

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
British Journal of Haematology|March 16, 2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myelomaNina Shah, Li Li, Jessica McCarty, et al.
Blood|July 24, 2014
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHDAhmad Khoder, Anushruti Sarvaria, Abdullah Alsuliman, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood|June 20, 2023
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsBing Z Carter, Po Yee Mak, Muharrem Muftuoglu, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Nature Medicine|April 28, 2022
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Genome Research|March 24, 2018
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutationsMaitri Y Shah, Manuela Ferracin, Valentina Pileczki, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Immunology|January 31, 2018
The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by LenalidomideHila Shaim, Zeev Estrov, David Harris, et al.
British Journal of Haematology|March 16, 2017
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myelomaNina Shah, Li Li, Jessica McCarty, et al.
Blood|July 24, 2014
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHDAhmad Khoder, Anushruti Sarvaria, Abdullah Alsuliman, et al.
Blood Cancer Journal|June 29, 2023
A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysisJayastu Senapati, Muharrem Muftuoglu, Jo Ishizawa, et al.
Blood|June 20, 2023
Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsBing Z Carter, Po Yee Mak, Muharrem Muftuoglu, et al.
Journal of Hematology & Oncology|July 8, 2023
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agentsNicholas J Short, Muharrem Muftuoglu, Faustine Ong, et al.
Blood|June 2, 2016
Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantationTakuya Sekine, David Marin, Kai Cao, et al.
Nature Medicine|March 4, 2022
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Nature Medicine|April 28, 2022
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapyIrene Ganan-Gomez, Hui Yang, Feiyang Ma, et al.
Genome Research|March 24, 2018
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA <i>CCAT2</i> induce myeloid malignancies via unique SNP-specific RNA mutationsMaitri Y Shah, Manuela Ferracin, Valentina Pileczki, et al.
Pageof 3